PRIMARY STUDY

Terpene-Enriched CBD oil for treating autism-derived symptoms unresponsive to pure CBD: Case report

Key Findings:  This case study is of an individual who had been successfully managing symptoms of Autism spectrum disorder with antipsychotics and oral cannabidiol (CBD), but as they aged, the current treatment became insufficient. Increasing dosing also did not improve symptoms; however, fortification of the CBD with anxiolytic and calming terpenes eventually lessened and eliminated the aggressive behaviors, suggesting the terpene profile and ratio may have more of an impact on symptom control.

Type of Study:  Meta-analysis

Study Sample Size:  1

Study Result:  Positive

Study Location(s):  Israel, Italy

Year of Pub:  2022


Cannabinoids Studied:  Cannabidiol (CBD), Tetrahydrocannabinol (THC), Anandamide (AEA), Fatty Acid Amide Hydrolase (FAAH)

Phytocannabinoid Source:  Cannabis Flower derived

Chemotype:  Chemotype III

Terpenes Studied:  ß-Caryophyllene, Limonene, Linalool, Nerolidol, Pinene

Receptors Studied:  CB1, CB2, GPCR 55, TRPV1, TRPV2, PPAR - Gamma, TRPs, PPARs

Ligands Studied:  Dopamine, Oxytocin, Serotonin

Dosage: Terpene enriched CBD (0.19 mg/kg of body weight)

Route of Administration:  Oral (Ingestion)



Link to study